64362-32-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzoyl-2-pyridinecarboxylic acid is used as an intermediate in the synthesis of various pharmaceutical compounds, including 5-methyl-N-aryl substituted-1,3-oxazolidine-2,4-dione derivatives. These derivatives exhibit potential biological activities and may be further developed into novel therapeutic agents for the treatment of various diseases and medical conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, 3-Benzoyl-2-pyridinecarboxylic acid is utilized as a key building block for the creation of complex organic molecules. Its unique structural features, including the presence of both a benzoyl group and a carboxylic acid group, make it a versatile starting material for the synthesis of a wide range of compounds with diverse applications in various industries, such as pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C13H9NO3/c15-12(9-5-2-1-3-6-9)10-7-4-8-14-11(10)13(16)17/h1-8H,(H,16,17)

Upstream product

• 101893-55-4 2-methyl-3-benzylpyridine 
• 78140-38-2 1-Hydroxy-2-methyl-1-phenyl-pyrro<3,4-b>pyridine-3(1H)-one 
• 104728-70-3 3-hydroxy-2,3-diphenyl-7-azaisoindolinone 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 100-58-3 phenylmagnesium bromide 
• 71-43-2 benzene 
• 6144-78-1 N-methylpyridine-2-carboxamide 
• 611-74-5 N,N-dimethylbenzamide 
• 109591-92-6 3-benzyl-2-methyl-piperidine 
• 100371-69-5 5-benzylidene-6-methyl-2,3,4,5-tetrahydro-pyridine 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 

Downstream Products

• 5424-19-1 3-Benzoylpyridine 
• 150348-53-1 5,7-Diphenylpyrido<2,3-d>pyridazin-8(7H)-one 
• 133030-40-7 3-Benzoyl-methylpicolinate 
• 3810-10-4 2-amino-3-benzoylpyridine 
• 876487-64-8 3-benzoyl-pyridine-2-carbonyl chloride 
• 211629-98-0 5-phenyl-pyrido[3,2-d][1,2]oxazin-8-one 
• 104728-69-0 3-benzoylpicolinanilide 
• 104728-71-4 3-hydroxy-2,3-diphenyl-7-azaisoindolinone hydrochloride 
• 87987-99-3 8-chloro-5-phenyl-pyrido[2,3-d]pyridazine 
• 211630-15-8 (5-phenyl-pyrido[2,3-d]pyridazin-8-yl)-hydrazine 
• 150348-54-2 7-ethyl-5-phenyl-7H-pyrido[2,3-d]pyridazin-8-one 
• 447425-12-9 7-isobutyl-8-oxo-5-phenyl-7,8-dihydro[1,7]naphthyridine-6-carbonitrile 
• 942984-19-2 3-benzoyl-pyridine-2-carboxylic acid (2-carbamoyl-phenyl)-amide 

Relevant academic research and scientific papers

Benzopyridazinone and pyridopyridazinone compounds

Benzo or pyridopyridazinones and pyridazinthiones of the formula STR1 wherein: X and Y are nitrogen or carbon, provided that at least one is carbon, and Z is oxygen or sulfur; R1 is hydrogen, lower alkyl, aryl, aralkyl, heterocyclo, heterocyclo lower-alkyl, heteroaryl, or heteroaralkyl; R2, R3, R4, R5 and R6 are independently selected from hydrogen, lower alkyl, halo, carboxy, alkoxycarbonyl, carbamoyl, lower-alkyl carbonyl, halocarbonyl, thiomethyl, trifluoromethyl, cyano or nitro; or a pharmaceutically acceptable ester, ether or salt thereof, have been found to be useful as an anti-inflammatory, antasthmatic, immunosuppressive, anti-allograft rejection, anti-graft-vs-host rejection, autoimmune disease or analgetic agent(s).

Tricyclic thiazole and oxazole derivatives and pharmaceutical agents containing them

The present invention concerns thiazolo- 2,3-a!pyrrole and oxazolo- 1,2-a!pyrrole derivatives of formula I STR1 in which HET represents a heterocyclic ring with 3-7 ring atoms which can be substituted by one, two or three residues R1 which can be the same or different, Y represents an oxygen or sulphur atom, or a SO or SO2 group, X can be an oxygen or sulphur atom, R denotes an aliphatic residue with 1-9 C-atoms which can be substituted by phenyl or denotes a phenyl ring or a carbocyclic ring with 7-15 C atoms or a heterocyclic ring system each having 5 or 6 ring atoms, in which the aforementioned phenyl rings, carbocyclic rings or heterocyclic ring system can be substituted once or several times, if desired, and R1-R5 denote hydrogen or an aliphatic residue, as well as their tautomers, enantiomers, diastereomers and physiologically tolerated salts.

Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyridopyridine

A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity.Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead 1a.Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyridopyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists.Among the compounds synthesized, N--7,8-dihydro-N,7-dimethyl-8-oxo-5-(substituted phenyl)-6-pyridopyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of 125I>BH-SP binding in human IM-9-cells) of 0.21-0.34 nM and ED50 values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg.These compounds exhibited significantly potent activity upon oral adiministration with ED50 values of 0.068-0.17 mg/kg.Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.

Application of Organolithium and Related Reagents in Synthesis, Part VI . A General Study of the Lithiation of Secondary Picoline- and Isonicotine Amides

The lithiation of secondary picoline- (1) and isonicotine-amides (2) and the subsequent reaction of the corresponding (N- and 3-)lithiated amides (3 and 4) with N,N-dimethylbenzamide towards the synthesis of the C3-benzoylated picoline (12a) an